Key Insights

Highlights

Treatment Research

3 treatments under study, led by Antimesothelin Cart Cells

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05531708Phase 1WithdrawnPrimary

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Showing all 1 trials

Research Network

Common Treatments

  • Antimesothelin Cart Cells1
  • Cyclophosphamide1
  • Fludarabine1

Active Sponsors

  • UTC Therapeutics Inc.1
  • Shanghai Pudong Hospital1

Top Investigators

Activity Timeline